RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.14M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.36M | — | $31.65M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 592.46K | — | $13.21M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 116.78K | — | $2.72M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 70.00K | — | $1.63M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Soros Fund Management ✦ | 30.00K | — | $697,800 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 13.00K | — | $302,380 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 52.47M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.15K sh · $35,167
Officer, Director · 3.38K sh · $108,106
Officer · 7.92K sh · $261,813
Officer · 2.08K sh · $70,043
Officer, Director · 1.95K sh · $76,230
Officer, Director · 43 sh · $1,765
Officer, Director · 215 sh · $8,570
Officer, Director · 1.07K sh · $49,190
Officer, Director · 7.14K sh · $325,308
Officer · 16.20K sh · $827,184
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology